title: In Vitro Activity of Ceftazidime-Avibactam against Contemporary Pseudomonas aeruginosa Isolates from U.S. Medical Centers by Census Region, 2014.
abstract: Thein vitroantibacterial activities of ceftazidime-avibactam and comparator agents were evaluated using reference broth microdilution methods against 1,743Pseudomonas aeruginosaisolates collected in 2014 from 69 U.S. medical centers, representing each of the nine census regions. Ceftazidime-avibactam demonstrated potent activity againstP. aeruginosa, including many isolates not susceptible to ceftazidime, meropenem, and piperacillin-tazobactam. In each of the nine census regions, ceftazidime-avibactam demonstrated the highest percentage of susceptible isolates.
authors.affiliation: JMI Laboratories, North Liberty, Iowa mike-huband@jmilabs.com.
authors.forename: Michael D
authors.initials: MD
authors.lastname: Huband
authors.affiliation: JMI Laboratories, North Liberty, Iowa.
authors.forename: Mariana
authors.initials: M
authors.lastname: Castanheira
authors.affiliation: JMI Laboratories, North Liberty, Iowa.
authors.forename: Robert K
authors.initials: RK
authors.lastname: Flamm
authors.affiliation: JMI Laboratories, North Liberty, Iowa.
authors.forename: David J
authors.initials: DJ
authors.lastname: Farrell
authors.affiliation: JMI Laboratories, North Liberty, Iowa.
authors.forename: Ronald N
authors.initials: RN
authors.lastname: Jones
authors.affiliation: JMI Laboratories, North Liberty, Iowa.
authors.forename: Helio S
authors.initials: HS
authors.lastname: Sader
mesh_terms: D000046:Academic Medical Centers; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D053961:Azabicyclo Compounds / Q000494:pharmacology*; D002442:Ceftazidime / Q000494:pharmacology*; D019352:Censuses; D004338:Drug Combinations; D006801:Humans; D000077731:Meropenem; D008826:Microbial Sensitivity Tests; D010397:Penicillanic Acid / Q000031:analogs & derivatives / Q000494:pharmacology; D010878:Piperacillin / Q000494:pharmacology; D000077725:Piperacillin, Tazobactam Drug Combination; D011552:Pseudomonas Infections / Q000188:drug therapy* / Q000382:microbiology; D011550:Pseudomonas aeruginosa / Q000187:drug effects* / Q000254:growth & development / Q000302:isolation & purification; D062486:Public Health Surveillance; D013845:Thienamycins / Q000494:pharmacology; D014481:United States; D018440:beta-Lactam Resistance / Q000502:physiology*
chemical_list: D000900:Anti-Bacterial Agents; D053961:Azabicyclo Compounds; D004338:Drug Combinations; D013845:Thienamycins; C000595613:avibactam, ceftazidime drug combination; D000077725:Piperacillin, Tazobactam Drug Combination; D010397:Penicillanic Acid; D002442:Ceftazidime; D000077731:Meropenem; D010878:Piperacillin
references.citation: Clin Infect Dis. 2002 Mar 1;34(5):634-40
references.pmid: 11823954
references.citation: Antimicrob Agents Chemother. 2007 Apr;51(4):1553-5
references.pmid: 17261621
references.citation: Antimicrob Agents Chemother. 2010 Jul;54(7):3072
references.pmid: 20421402
references.citation: Crit Care. 2010;14(3):224
references.pmid: 20594363
references.citation: Trends Microbiol. 2011 Aug;19(8):419-26
references.pmid: 21664819
references.citation: Lancet Infect Dis. 2016 Feb;16(2):161-8
references.pmid: 26603172
references.citation: Antimicrob Agents Chemother. 2014;58(2):833-8
references.pmid: 24247134
references.citation: Antimicrob Agents Chemother. 2015 Feb;59(2):1020-9
references.pmid: 25451057
references.citation: Antimicrob Agents Chemother. 2015 Mar;59(3):1789-93
references.pmid: 25534728
references.citation: Diagn Microbiol Infect Dis. 2015 Dec;83(4):389-94
references.pmid: 26162518
references.citation: Drugs. 2013 Feb;73(2):159-77
references.pmid: 23371303